[ad_1]
Some people have few symptoms and recover quickly, while others end up on the bed surrounded by towels, and those with low immunity or breathing problems may be at risk.
We are all excited to see a cure for colds, but it seems that his arrival does not happen.
– What is the inhibitor then? Will we do it soon?
Common colds are caused by many types that cause throat pain, headaches, coughing and sneezing.
Sufferers of symptoms may be more common in men, a so-called "male flu," a theme for another day.
The most common cause of colds is rhinovirus, which accounts for 50% of the infection (not called rhino, but of the Greek word meaning nose).
Children are usually between 8 to 12 times a year, while adults are two to three times.
Some other viruses can cause common colds such as adenovirus, respiratory syncytial virus and influenza virus.
But for the most subtle scientists in this field, the first challenge for them is to eliminate the nasal virus (rhinovirus).
-Nasal Virus Note:
The nasal virus is not just a single basilisk: there are currently more than seventy-one different strains, and it is very difficult to make a vaccine or antiviral: there are approximately 90 to 95 antiretrovirals, which is a much lower proportion of antibiotics (antibiotics), and there are no antiviral drugs approved to eliminate the nasal virus.
Some of them have proven effective against some breeds, but they are ineffective against other breeds, and the chances of a virus that can kill them directly are very small at the moment .
A number of groups around the world are working hard to find useful solutions, and these solutions contribute to a report that documents the latest developments on the subject.
Many groups try to treat proteins in host cells because they are the most common place for viral replication, and this can be the effective way of stopping the spread of the virus to other people. Other cells in the body.
A very recent hope emerged from the Imperial University of London, a plant compound that targets enzymes in virus-infected cells, known as NMT1 and NMT2, and prevents it from occurring. Be used as a breeding ground for viruses.
Another team from Canada is working on a compound capable of inhibiting different types of human enzymes, called PI4KB This enzyme is necessary to supplement the reproduction of the virus.
Several teams from the United States and the Perbright Institute, in southern England, are also working differently: they are trying to prevent infection by using certain antibodies, called neutralizing antibodies, which act against different proteins of the virus.
But the number and variants of the nasal virus in the world mean that a total antibody must be developed.
Talk excited!
My research group is trying to solve the problem from another angle.
We are working on a family of molecules called host defense peptides or antimicrobial peptides, which are part of the first line of defense of the immune response to viruses, and in addition to their presence in humans. they are also present in many mammals, plants and insects.
We and others have demonstrated the ability of these peptides to kill a wide range of bacteria, fungi and viruses.
For example, one of our studies showed that a peptide in the human immune system called cathelicidin has a high efficacy in killing influenza virus compared with anti-influenza drugs.
And very recently, we have verified that the same peptide Cathylicidin (cathelicidin) in humans is capable of killing the nasal virus, and we were happy to find out.
We also found that other animals' cathelicidines (such as pigs) were very effective at killing the human virus, and this also increased the hope that the immune system peptides would be more effective. other mammals were able to fight the infection.
However, this is only the first step of a long way, and we now hope to modify these peptides to make them more stable and more effective, not only against the nasal virus and the flu, but also against other types of cold viruses.
Up to now, our work is still at the lab table, and against only a common strain of the nasal virus, the next step will be performed on animals, and then on human clinical trials.
and each of the three approaches described in a near phase of development, because it is very difficult to frame these things chronologically, but there may be a possible production of a viable treatment in about five to ten years.
But until the day we get rid of colds, we will have to be very careful: we should establish a parallel line with antibiotics, such as increasing antibiotic resistance, the same with the viral treatments.
It would be imprudent to distribute the cold treatment to both the patient and the patient, but rather suggest to keep it for those who are in dire need of it, such as those who suffer from asthma and those who have a low immunity.
The rest of us will probably have to continue to resist them in the slowest way, with boxes of towels, natural tusks and too many hot drinks.
- [modifier] [modifier] [modifier] [modifier] [modifier] [modifier] [modifier] [modifier] {return;} js = d.createElement (& # 39; script & # 39;); js.id = id; js.async = true; js.src = "http://connect.facebook.net/ar_AR/all.js#appId= & xfbml = 1"; d.getElementsByTagName (& # 39; head & # 39;) [0] .appendChild (js);} (document));
[ad_2]
Source link
